Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational ONIVYDE as a second-line treatment for small cell lung cancer at the IASLC 2019 World Conference on Lung Cancer

Posted in Biotech

September 09, 2019 • 0 min read

– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint). Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint)....

Poop-testing startup uBiome was once valued at $600 million by Silicon Valley’s top VCs. It just filed for bankruptcy.

Posted in Biotech

September 06, 2019